An experimental weight-loss drug from Eli Lilly & Co. helped patients lose weight with few side effects, according to the ...

Epcoritamab demonstrated a median CR of 36 months and a median progression-free survival of 37 months in LBCL patients.

Called enpatoran, the agent targets the Toll-like receptor (TLR) species 7 and 8. Some 50%-60% of patients with systemic ...

BARCELONA -- The oral drug deucravacitinib (Sotyktu) passed what is probably its final test as a treatment for psoriatic ...

50 Gemini Nail Ideas for the Zodiac’s Ultimate Trendsetter originally appeared on Parade.

I’ll never forget the first time Brian Wilson made me see God. It was 1973, and I was sitting in the mostly empty balcony of ...

Enjoy 12 digital issues a year from the global design authority Choose a print or digital subscription, or both ...

Roman shoppers have found a stylish summer top that has an 'excellent fit' and non-crease fabric. The V-neck Button Tunic Top ...

Eli Lilly's (LLY) experimental obesity drug, eloralintide, shows up to 11% weight loss in 12 weeks with minimal side effects in early-stage trial. Read more here.

It is not only humans that can speak; the world of nature, i.e, trees, water, and seasons  also emit sounds, and  try to ...

Critics Rating: 3.5 stars, click to give your Rating/Review, If you’re drawn to real-life cautionary tales where human ambition collides with nature’s unforgivin ...

After a long time of hemming and hawing, the Senate president of the 19th Congress, Francis Escudero, finally took his oath ...